VERAXA Biotech AG (NASDAQ: VRXA) has taken another step forward in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI). The regulatory feedback provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan for its lead therapeutic program, according to a press release on July 20.
The Scientific Advice procedure allows drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The positive feedback from PEI supports the proposed development strategy for the BiTAC(R)-TCE candidate, which previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
VERAXA is an emerging leader in designing novel cancer therapies, focusing on next-generation antibody therapeutics. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances its most advanced BiTAC(R)-TCE candidate toward future clinical development.
For more information, visit the company's newsroom at https://ibn.fm/VRXA. The full press release with details on the regulatory feedback is available at https://ibn.fm/zBiDU.
